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OBJECTIVE — We hypothesized that insulin detemir mixed with aspart had equivalent
effects on blood glucose as if being given as separate injections in pediatric type 1 diabetes
patients.
RESEARCH DESIGN AND METHODS — Fourteen children with type 1 diabetes were
randomly assigned to either Study A (mixed insulins) or Study B (separate insulins) for the ﬁrst
10 days and crossed over for the last 10 days. Each subject underwent continuous glucose
monitoring on the last 72 h of each study.
RESULTS — The 48-h area under the curve (mmol/hour/l), M-value, and mean amplitude of
glucose excursion (mmol/l) for Study A versus Study B were 457  70 versus 469  112 (P 
0.58),39.6715.37versus39.759.69(P0.98),and6.351.92versus5.980.92(P
0.42), respectively.
CONCLUSIONS — Insulin detemir mixed with aspart had equivalent effects on blood glu-
cose versus giving them as separate injections in children with type 1 diabetes.
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O
ne of the barriers to good glycemic
control in children with type 1 dia-
betes is multiple daily insulin injec-
tions(1,2).Mixingrapid-actingandslow-
acting insulins in the same syringe would
decrease the number of injections and
may improve adherence (3,4). Although
there are concerns that mixing the insu-
lins would change the glucose excursion
(5),mixingrapid-actinginsulin(aspartor
lispro) with slow-acting insulin glargine
in the same syringe immediately before
use did not change the glucose excursion
and rates of hypoglycemia (3,4). We hy-
pothesized that slow-acting insulin det-
emir mixed with aspart would have
equivalenteffectsonbloodglucoseversus
giving them as separate injections in chil-
dren with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the institutional review board
of the Baylor College of Medicine. The
study was designed to detect a 20% dif-
ference in mean area under the curve
(AUC) for blood glucose values in the
72-h study period. We assumed the r 
0.7 between repeated measures and that
the SD for our excursion measure AUC
was 30%. With these speciﬁcations and
assuming a 45% drop-out rate, we re-
quired 20 subjects to achieve the ﬁnal
necessary sample size of 11 subjects.
Eighteen pediatric subjects with type 1
diabetes (11 males and 7 females) were
recruited for this 20-day, randomized,
crossover, and open-labeled study. These
subjects were aged 14.75  2.69 years
andhadA1Cof7.70.7%.Theﬁrstfour
subjects were aged 16 years and older as
required by the U.S. Food and Drug Ad-
ministration.Thesubjectswererandomly
assigned to either Study A (mixed insu-
lins) or Study B (separate insulins) for the
ﬁrst 10 days. They were then crossed
over for the last 10 days. Each subject
underwent 72 h of continuous glucose
monitoring (CGM) using CGMS iPro
(Medtronics, Minneapolis, MN) on the
last 72 h of Study A and Study B. Data of
48 h from midnight of the 1st day to mid-
night of the 3rd day of the 72-h CGM
were used for analysis to ensure the same
starting and ending times of monitoring
for all subjects. The relative frequency of
mild hypoglycemic episodes was calcu-
lated as the number of glucose values be-
tween 40 and 60 mg/dl divided by the
total number of glucose values generated
during the chosen 48 h of CGM. Sus-
tained glucose values over time were cal-
culated as AUC, index of blood glucose
controlasM-value,andglucoseexcursion
as mean amplitude of glucose excursion
(MAGE). The 48-h M-value for each
treatmentofeachsubjectwascalculated
using the formula M  M
BS  M
W,
whereM
W(maximumbloodglucose
minimum glucose)/20; M
BS  the mean
of MBSBS; MBSBS  individual M-value
for each blood glucose value during the
48-h period and was calculated as (abso-
lute value of [10  log(blood glucose val-
ue/120)])
3 as being done for 24-h data by
Schlichtkrull et al. (6). The 48-h MAGE
foreachtreatmentofeachsubjectwascal-
culated by modifying the method pro-
posedbyServiceetal.(7)forCGMdataas
follows: summation of absolute value of
[blood glucose  48-h mean blood glu-
cose]  1 SD/n, where n  number of
absolute value of [blood glucose  48-h
mean blood glucose] being greater than 1
SD. The 48-h AUC, M-value, or MAGE
were compared between Study A and
Study B by paired t test. Signiﬁcance was
chosen to be P  0.05. Data were ex-
pressed as means  SD. The Wilcoxon
signed rank test was used to compare the
incidence of hypoglycemia in the two
treatment groups. GraphPad Prism
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used to analyze the data.
RESULTS— Fourteen subjects com-
pleted this 20-day, randomized, cross-
over, open-labeled study. One male
subject dropped out because of a very ac-
tive sports schedule and could not con-
tinue participation. Three subjects (two
males and one female) had trouble with
the CGM tracing and, therefore, were ex-
cluded from the ﬁnal analysis. Figure 1
shows 48-h CGM tracing for 14 subjects.
AUC was 457  70 mmol/hour/l for
Study A compared with 469  112
mmol/hour/l for Study B (P  0.58). The
M-value was 39.67  15.37 for Study A
compared with 39.75  9.69 for Study B
(P  0.98). MAGE was 6.35  1.92
mmol/l for Study A compared with
5.98  0.92 mmol/l for Study B (P 
0.42). Relative frequency of mild hypo-
glycemic episodes was 5.3  5.2% for
Study A versus 6.7  11.1% for Study B
(P  0.95). There was no severe hypogly-
cemia in either group.
CONCLUSIONS — In this study, we
present data showing that insulin detemir
mixed with aspart given twice daily had
equivalent effects on blood glucose when
compared with giving detemir and aspart
as separate injections twice daily in chil-
dren with type 1 diabetes. There was no
increase in hypoglycemia in either treat-
ment.Furtherstudiesareneededtostudy
the long-term consequences of mixing
and the effect on glycemic control.
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